SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) and Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Risk & Volatility
SAB Biotherapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for SAB Biotherapeutics and Kalaris Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SAB Biotherapeutics | 1 | 0 | 3 | 1 | 2.80 |
| Kalaris Therapeutics | 1 | 1 | 0 | 1 | 2.33 |
Valuation & Earnings
This table compares SAB Biotherapeutics and Kalaris Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SAB Biotherapeutics | $1.32 million | 23.90 | -$34.10 million | ($4.00) | -0.76 |
| Kalaris Therapeutics | N/A | N/A | -$58.77 million | ($4.05) | -1.20 |
SAB Biotherapeutics has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares SAB Biotherapeutics and Kalaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SAB Biotherapeutics | N/A | -153.92% | -89.16% |
| Kalaris Therapeutics | N/A | -81.02% | -65.15% |
Summary
SAB Biotherapeutics beats Kalaris Therapeutics on 8 of the 12 factors compared between the two stocks.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
About Kalaris Therapeutics
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
